Lipoprotein(a), stability of coronary reperfusion and efficacy of thrombolytic therapy  by Harder, A.W. & Davies, G.J.
We measured hpopretoms, low.density hpoprolem (LDL) subclasses and 
part,tie size, hpopreloin (a), homocystemo (Hcys), and markets of thremboszs 
and fibnnolysis in 22 oealthy o!derly men ~ago 74 ~ 3 years, mean 
SO), before and alter 9 weeks of treatment with 05, t n, ~ mg,'day O1 oral 
m~cromted 17/~-estradiol 
Restdt~: LDL-C I-6%), apo.B ( 9%), fnglyceride ( 5%), VLDL-TG 
( - ! 9%) 8nd Ho/s ( - 11%) coneenffahons decreased w~th estradtot, whereas 
HDL-C (*14%) and HDL~-C (*55%) increased Lipoprotein (a) d~d not 
ch,~nge. Fibenogen (13%)  and p!asmln(~gen activator inhibitor.1 (PAl.l) 
(26%)  C~noeflf~ations decreasecl There were no changes ~n thrombotK: 
matkem including thrombln-ant!thrembm I!1 complex, prothrombm fragment 
t 2, O.dim0r, anhthfombm activity, preteln~C an~ S and yon Willebrand factor 
set!pen 
Va~btes Pte-eli1~ogen PO-~t~E~OO~I~, % Ch~lnge p vah~e 
(rne<tn ~ SD) irl~an ~ SOl 
LDL-C~t  14t ~ 2t] 132 ~ 30 63 ~ 12 = 0007 
IG mgd~ t30 s ~ 11.~ ~ 41 4 7 ~. ~0 : O 01 
HDL.C ~.'dt 47 t 0 S3 t I0 .t4 z 12 -1) 001 
HDL3.C n~'~l 23 ~ 13 29 ~ 13 .55 : 72 -0003 
HDL3"C m~2/dl 30 ~ ? 27 ~ (~ a 4 ~ tO ; 0 001 
LOLs~e (nml 207 ~O6 2oa ~ 06 9fi ~ a o0ot 
Hc'y~ ti,M) 67 ~ 3 76 ~ 2 I 1., 09 - OOOt 
CortCtu$iOn. We conclude that k'~v (~se estrogen in men reduces low-den- 
sity hpoprotems, homom/steine tibnn(~en and PlA-1 concentrations w~thout 
.ncfeas=ng markers of thrombotic ~sk 
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~ Lipoprotein(a), Stability of Coronary Reperfuslon 
and Efficacy of Thrombolytic Therapy 
AW Harder. G.J. Davies. Card~otogy D~.~s~en. RPMS Hammersm~th 
HOSl~tal London. UK 
Background: Lq:~,c'~retemt:t~ ',Lpa) promotes atherothrembos=s, however, stud- 
~es dunncj acute my~T, ard~al ..-ttarct=on (AMI) remain mcenclusnte We mves- 
bgatecl the relationship between Lpa and efficacy O1 thromb~lyl~c therap'y 
dunng AM= 
,~c-~; :  Twenty six patients 117 men. 9 women, mean age 57 : 2 years) 
admitted with AM| re~mved i v t-PA (30-60 Mega Units) w~thm 6 hours at the 
onset of Symptoms Coronary recanai=zat~on (TIMI grade 3) was assessed 
by senal adenography and ~n~nuou~ 2 channel ST segment recording was 
used to momtor the stabddy of coronary reperfusmn All pat~enLs received 
oral aspmn and =v hepann Baseline pretreatment Lpa and serum hp~d 
~eveLs were measu(.'~cl Patients ,~ere dtvldecl =n 2 groups: Group 1 ILpa 
levels ::25 mg.,'dl, n = 12) and Group 2 ILpa levels - 25 mg.'dl, n = 14) 
Resuits Age. sex. treatment delay from symptom onset. 90 minute TIMI 
grade and hp=ds levels ~ere similar ~n the 2 groups However. coronary 
recanahzafton time (mean : SD) was significantly prolonged cn group 1 
compared to patients m group 2 t51 = 16 vs 30 ; 17 rain p = 005) 
Recanalizahon t~me correlated pos=hvely w~th Lpa levels (r . 0.9. p ~ 0001 ). 
The number (5 : 1vS. 1 =05.  p - 002) and magmtude (31 ~: 1 mmvs. 
1.2 ~ 1 ram. p .  005) OI recurrent ST elevahon following thrombelysls was 
greater m grOup 1 cOmpared to group 2 
Conclusions: Elevated Lpa =s assooated with delayed and unstable coro- 
naw repedus~on toltowmg ~ v tPA 
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[ 845- i_~ I Rates and Predictors of Embolic Events Following 
Electrical Cardloverslon 
F. Genhle, B.K. Khandhena, KR. Bailey. C Lohse. J.8. Seward. A Jamd 
Taiik. Mayo Chn~c and M,tVO Foundat;on. Rochester. Mmnesota. USA 
Wide vanations (1-7%) in reported rates of embolic events lEE) following 
electrical cardioversion (ECV) exist in the literature. To evaluate EE nsk in 
the Mayo ECV practice, all ECVs (1053. 66% male. mean age 66 = 12.5 
years) between 1990-1994 were studied. Patient as well as atrial tibnllafion 
and anticoagulation (AC) characteristics were recorded. Adequate AC was 
defined as therapeutic International Normalized Ratio / Partial Thromboplas- 
tin -time. AC consisted of warfarin (63.0%). heparin (118%). born (15.9%), 
and none (9.3%). Successful ECV was achieved in 892 pts (85%) who form 
the basis for analysis. The rat3 of EE occurrence within 30 days was 0.78% 
(CI 0.32-1.62%). Two (2.1%) of these occurred in 94 no-AC pts (p = 0.012 
compared to AC pts) The rates of EE wore 027% m ad~uatety ant=co. 
agulated pls versus 1 68% ,n m~dequatety anllcoagutated pts (p = 0 0491 
All 7 events occurred =r, the 51% pts with hypedens~on (p = 0 OCt. ) Four 
occurred in 142 diabetic pts iP 0 001 ) History of coronary affery d~sca~.c~ 
and hyperl=p=dem~& were also segndcant (p 005) corretat~ ot EE Two 
O1 7 events OCCurred among 31 pts with severe letl atna! enfarsement (p .  
0 05) 
Cantles!ads 1) Ovmal! rate of EE following ECV m 0 78%= 2) adequate 
AC at the t~me O1 ECV results in lower rates o1 EE (027%); 3) hypertens~Onr 
d~abetes, and severn loft at~!! enla~rgement am associated with h igher  rates 
O1 EE following ECV: and 4) higher rates of EE (2 t%) are noted m pt~ 
not re~oiwng any AC ECV is ~ safe procedure when pts are adequately 
anl=coagutated 
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~ Hypertens!on Strongly Predict= Early Relapse Atter 
Elective Card!ovemlon of Air!a! Fibrillation 
L O'Toele, A. Wilhams, TR D ,Shaw, IR  Starkey, DB Nodhndge Depfot 
Card~o/og~, Western General Hosl~fat, Ec~nburgh. UK 
Background There h~ been a marked recent mcrea~e =n the use O1 electwe 
DC Cardmvers=on IDCCV) for atnal flbnllstlon (AFt We reviewed our pract*ce 
dunng 1996 to identdy chmcal factors which predict maintenance ol sinus 
rhythm (SR) at st~, week follow up (FU) 
Method: Case note rewew of 88 elective admms~ons for DCCV 
Results: 40% O1 patients had hyperlens=on (PIT) 40'% O1 patients were 
taking am~octarone peer to DCCV Immediate mstoratfon at SR was ach~evecl 
=n 88% O1 attempts but only 47% ot the tctat had maintained SR at FU 
In the 63 patrents undergoing DCCV for the first time, tact'ore pred,.ctmg 
maintenance of SR at FU were re~ewecl Age. sex, the presence ot CAD. 
impaired LV function ard use at digoxln did not predict mmntenance at SR 
3=;.~,*.~n .-,I AF ~rongty predicted maintenance O1 SR at FU (AF clura0on - 6 
months 84%. • 6 montt's 32%; p ~ 0 001 ) as did a d=agnos~s of PiT (SR at FU 
PIT 27%, non-HT 70%; p ~ O001) and use et amiodarene (SR at FU 74% 
vs 38%, p = 0002) After adiustment for durahon of AF or use O1 am~odarone 
the relabonsh~p between a diagnosm of HT and tadure to maintain SR at FU 
became even stronger (duration ac~Jsled odds rat~o; HT vs non-HT pat=eats 
12.6; p - 0.001 amlodarone adius~ed odds rat~o .54: p = O 004) 
Cencl'.~on The pr~pomon O1 I-IT patients cn th~s senes =s h~ghe[ than 
reported pre'.qousty, but similar to that m population-based studies of AF The 
chance of maintaining SR after DCCV =n HT patients =s unacceptably low 
Measures to improve outcome include early DCCV and pre-treatment with 
am~oclarene 
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~ 845-3  i The  Cl inical  Exper ience  With the Metr lx Automat ic  
' Imp lantab le  Atr ia l  Def ibr i l lator  
R Tavem~er, L Jordaens For the Metnx Ir~,est~gators. Umversffafr 
Z~ekenhu~s Gent. Gent. Belgium 
Transven~us atnal defibnllahon has been shown to be efficacious for the 
acute termination of episodes of areal fibnllal~on (AF). However, no data 
exist as fo whether repeated transvenous defibnllatlon using an aulomstlC 
cmplantable atrial defibnllator (laD) would be efficamous. Therefor~ the pur- 
pose O1 this chmcal teal was to evaluate the clinical use O1 the Metnx lAD 
m patients (pts) with uprsod~c, symptomatic AF refrecto~/ tO drug therapy. 
The device and Its 3 leads system (Penmeter nght sinai, Penmeter cereno~ 
sinus delibnllat~on and right ventncular bipolar leads) were ~mplanted in St 
pts (40 mares and 11 females). On average these patients had taken 39 
ant~arrhylhm~c drags that had fa~led to control AF recurrence or were found 
to have intolerable s~de effect These pts were without significant StruC~urat 
head d~sease and shghtly enlarged nght stnum (mean LA size 4 4 ~ 0 8 
cm). Dunng the study penocl of 20 months (mean pt follow-up 259 : 138 
days), 41 pts have exbenenced 252 spontaneous AF episodes (SE) with 
an average of 6 episodes per patient Excluding the throe epcsode5 that 
were !rested dunng ADFT testing. 675 synchron=zc"d shocks have been de- 
livered for the remmmng 249 SE (average 27 shocks per epcsode) with no 
ewdenoe of ventncutar prearrhythm~a One pstcent had a shock dehvered 
and had subsequent spontaneous conversion pnor to full delivery of ther- 
apy. One pabent had 4 SE where AF recurred shodly after the sucCesstul 
conversions. Three of these episodes were terminated with pharmacologi- 
cal interventions and one episode was terminated spontaneously. D~l;~ from 
these 8 episodes, including the 3 treated dunng ADFT testing, were ex- 
cluded =n the efficacy calculabons. The device has successfully terminated 
95=0 of the episodes although some patients had AF recurrence ~hortty ~; 
tar successful detibnllation. Taking th~s recurrence of AF into consideret¢on. 
the clinical efficacy of the defibnllat~on therapy was 77.4%. One pabent. 
due to frequent SE (1-2 per week) unaffected by the device unden,~ent AV 
junctional ablation with permanent pacing Prompt termmatren of AF has 
